RxDoctor Payments Data

Ellen Song, MD

Pediatrics · Irvine, CANPI 1528079589

Payments from drug & device makers

$2,444in general payments, 2019–2025

Across 99 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$463
  • AstraZeneca$460
  • AbbVie$351
  • Medtronic$207
  • Eisai Inc.$168
  • Novo Nordisk$134
  • plus $661 from 14 others

What the payments were for

  • Travel & lodging$1717%
  • Food & beverage$2,24892%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,444 in reported general payments places this provider in the 90th percentile of 5,539 pediatrics providers in California.

See all pediatrics providers in California

Medicare billing

Part B allowed, 2024
$55,218
Medicare patients
103
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$36,383
EliquisApixaban32$24,717
XareltoRivaroxaban14$15,585
Breo ElliptaFluticasone/Vilanterol28$11,267
BelsomraSuvorexant16$8,825
Spiriva RespimatTiotropium Bromide12$6,352
SynthroidLevothyroxine Sodium50$3,513
Estradiol (Twice Weekly)Estradiol20$2,394
Celecoxib37$1,795
ValacyclovirValacyclovir Hcl31$1,440
Pantoprazole Sodium81$1,295
DottiEstradiol13$1,236
Propranolol Hcl ErPropranolol Hcl11$1,023
Zolpidem Tartrate ErZolpidem Tartrate11$982
Amitriptyline Hcl60$901

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$27$36,38335 claims
PfizerEliquis$19$24,71732 claims
AbbVieSynthroid$351$3,51350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,539 pediatrics providers in California.

Other pediatrics in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →